SCHEMBL4592299

SCHEMBL4592299

OCc1cncc(-c2ccc(OC(F)(F)F)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.61
CYP11B1 P15538 3/20 0.56
CYP11B2 P19099 3/20 0.56
SCN10A Q9Y5Y9 1/20 0.48
ABL1 P00519 6/20 0.45
FFAR4 Q5NUL3 1/20 0.43
PIP4K2A P48426 1/20 0.43
OPRM1 P35372 1/20 0.43
KCNH2 Q12809 1/20 0.43
FDPS P14324 1/20 0.42
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
PPARD Q03181 1/20 0.41
AURKA O14965 1/20 0.40
TPX2 Q9ULW0 1/20 0.40
CHRM5 P08912 1/20 0.40
SCN5A Q14524 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4592087 0.85 PRMT6 (0.61) PRMT6CYP11B1CYP11B2SCN10AABL1
SCHEMBL8027367 0.80 PPARA (0.49) FFAR4AURKATPX2
SCHEMBL16675835 0.80 CYP11B1 (0.78) CYP11B1CYP11B2
SCHEMBL4591858 0.80 CYP11B1 (0.51) CYP11B1CYP11B2FDPS
SCHEMBL21377112 0.78 PRMT6 (0.54) PRMT6CYP11B1CYP11B2SCN10AABL1
SCHEMBL1582822 0.77 CYP11B1 (0.59) CYP11B1CYP11B2SCN10AFDPS
SCHEMBL30430478 0.77 SCN5A (0.43) PRMT6SCN10AFFAR4KCNH2CA12
SCHEMBL1230338 0.76 CYP11B1 (0.53) PRMT6CYP11B1CYP11B2SCN10AABL1
SCHEMBL4187626 0.76 ABL1 (0.47) PRMT6CYP11B1CYP11B2ABL1OPRM1
SCHEMBL508392 0.75 KCNH2 (0.42) PRMT6SCN10AFFAR4KCNH2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429605-B2 Phenylpyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-30 US disclosed
CN-101213186-A Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-07-02 CN disclosed
EP-1912969-A1 PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-04-23 EP disclosed
WO-2007017169-A1 PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-15 WO disclosed
US-20070032530-A1 Phenylpyridine derivatives HOFFMANN-LA ROCHE INC. 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032530-A1 Phenylpyridine derivatives CYP3A5, QDPR, DPYD PRMT6 1357/4885CYP11B1 127/4885CYP11B2 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.